Current Report Filing (8-k)
April 03 2020 - 4:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): April 3,
2020
CELLULAR BIOMEDICINE GROUP, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-36498
|
|
86-1032927
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
1345 Avenue of the Americas, Fl15
New York, NY
|
|
10105
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (347) 905
5663
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
|
|
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
|
CBMG
|
The Nasdaq Global Select Market
|
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD
Disclosure.
On
March 31, 2020, a drug application was accepted by the National
Medical Products Administration of China (NMPA) for clinical trial
in China for the anti-BCMA CAR-T for relapsed or refractory
multiple myeloma (CAR088) by Cellular Biomedicine Group, Inc. (the
“Company”).
The
information furnished under this Item 7.01, shall not be deemed
“filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or subject to the liabilities of
that section. The information shall not be deemed incorporated by
reference into any other filing with the Securities and Exchange
Commission made by the Company, regardless of any general
incorporation language in such filing.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Cellular Biomedicine Group, Inc.
|
|
|
|
|
|
Date:
April 3, 2020
|
By:
|
/s/ Bizuo
(Tony) Liu
|
|
|
|
Bizuo
(Tony) Liu
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024